SNRNP70 regulates the splicing of CD55 to promote osteosarcoma progression

Osteosarcoma (OS) is the most common malignant bone tumor, characterized by a high propensity for metastasis. Recent studies have highlighted the role of alternative splicing in cancer metastasis, although the precise mechanisms underlying aberrant splicing in OS invasion and metastasis remain uncle...

Full description

Saved in:
Bibliographic Details
Published in:JCI insight 2024-12, Vol.9 (24)
Main Authors: Li, Wenyue, Wang, Linzhu, Tian, Wen, Ji, Weihang, Bing, Danyang, Wang, Yan, Xu, Bingqian, Feng, Jiayue, Zhang, Peng, Liang, Haihai, Gu, Yunyan, Yang, Baofeng
Format: Article
Language:English
Subjects:
Alternative Splicing - genetics
Animals
Bone Neoplasms - genetics
Bone Neoplasms - metabolism
Bone Neoplasms - pathology
Cell Line, Tumor
Cell Proliferation - genetics
Disease Progression
Female
Gene Expression Regulation, Neoplastic
Humans
Male
Mice
Osteosarcoma - genetics
Osteosarcoma - metabolism
Osteosarcoma - pathology
Ribonucleoprotein, U1 Small Nuclear - genetics
Ribonucleoprotein, U1 Small Nuclear - metabolism
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteosarcoma (OS) is the most common malignant bone tumor, characterized by a high propensity for metastasis. Recent studies have highlighted the role of alternative splicing in cancer metastasis, although the precise mechanisms underlying aberrant splicing in OS invasion and metastasis remain unclear. Here, we analyzed consistently differentially expressed genes and differentially alternative splicing events between primary and metastatic OS to identify potential genes associated with OS progression. U1 small nuclear ribonucleoprotein 70K (SNRNP70) emerged as both differentially expressed and spliced, with elevated SNRNP70 levels correlating with poor prognosis in pateints with OS. Functional experiments demonstrated that SNRNP70 overexpression enhanced the proliferation and metastasis of OS cells in vitro, while its depletion reduced these capabilities in vivo. Mechanistically, SNRNP70 directly interacted with CD55, modulating its alternative splicing and promoting tumor progression in OS. Additionally, metastatic OS samples exhibited increased infiltration of resting immune cells, and single-cell RNA sequencing revealed communication between SNRNP70-expressing osteoblastic cells and macrophages via the ADGRE5/CD55 signaling pathway. Overall, our results showed that SNRNP70 knockdown inhibited OS progression, which was associated with the splicing of CD55, indicating SNRNP70 as a promising target for OS treatment.
ISSN:2379-3708
2379-3708
DOI:10.1172/jci.insight.185269